|
Homocysteine and Folic Acid Prescription Effects on Cardiovascular Diseases
|
Mehri Aliasgharpour *   , Fatemeh Miraliyari |
| Ministry of Health and Medical Education, Faculty Member of Biochemistry, Tehran, Iran |
|
|
Abstract: (7090 Views) |
Introduction: Homocysteine, is a sulfhydryl-containing amino acid that is typically present in very small amounts in all cells of the body. Many investigations have indicated hyperhomocystenemia as a risk factor, which is correlated with complications such as atherosclerosis, cardiovascular disease (CVD), and stroke. The aim of the present work was to review different studies for the lowering effect/s of folic acid supplementation on plasma homocysteine levels.
Methods: An academic search was conducted in number of electronic databases such as EMBASE, PubMed, and etc. for the key words; homocysteine , vitamin B12 , vitamin B6 , folic acid (vitamin B9) and cardiovascular diseases during years 2004 to 2018.
Findings: Review of the selected papers indicated that increased homocysteine levels as a risk marker for cardiovascular diseases, is associated with atheriosclerotic outcomes. In addition, it is considered a higher risk of coronary artery disease in patients with chronic renal dysfunction. In apparent contrast, however, another study indicated no risk reduction in homocysteine-lowering trials based on prescription of folic acid and concluded that intake of high amounts of folic acid may be beneficial via the homocysteine lowering, but may also be harmful via destabilization the atherosclerotic plaque.
Conclusion: The authors conclude uncertainty of whether or not folic acid means of homocysteine lowering forms of therapy will reduce the risk of CVD remains a main focus of future research works. |
|
| Keywords: Homocysteine, Methionine, Cysteine, Atheriosclerosis, Cardiovascular Disease. |
|
|
Full-Text [PDF 299 kb]
(1851 Downloads)
|
|
Type of Study: Research |
Subject:
General
|
|
|
|
|
|
|
| References |
|
1. 1.Faeh D. Chiolero A. Paccaud F. Homocysteine as a risk factor for cardiovascular disease: should we (still) worry about it? Swiss Med Wkly. 2006; 136:745–56.
2.Schaffer A. Verdoia M. Cassetti E. et al. Relationship between homocysteine and coronary artery disease. Results from a large prospective cohort study. Thromb Res. 2014; 134:288-93.
3. Baszczuk A. Kopczynski Z. Hyperhomocysteinemia in patients with cardiovascular disease . Postepy Hig Med Dosw. 2014; 68:579.
4.Guo H.Chi J. Wang P. Influence of folic acid on plasma homcysteine levels and arterial endothelial function in patients with unstable angina. Indian J Med Res .2009;129 (3):279-84.
5.Shenov V. Mehendale V. Prabhu K. Shetty R. Rao P. Correlation of serum homocysteine levels with the severity of coronary artery disease. Ind J Clin Biochem. 2014; 29(3):339–44.
6.Curro M. Gugliandolo A. Gangemi C. et al. Toxic effects of mildly elevated homocysteine concentrations in neuronal like cells. Neurochem Res.2014; 391:485-95.
7.Hankey GJ. Ekelboom JW. Homocysteine and vascular disease. Lancet. 1999; 354:407-13.
8.Palmieri EA. Fazio S. Lombardi G. Biondi B. Subclinical hypothyroidism and cardiovascular risk: a reason to treat? Treat Endocrinol. 2004;3 (4):233-44.
9.Mangge H. Becker K. Fuchs D. Gostner JM. Antioxidants, inflammation and cardiovascular disease. World J Cardiol. 2014 ;6(6):462–77.
10.Zhang S.Yong –Yi B. Luo LM.et al. Association between serum homocysteine and arterial stiffness in elderly: a community based study. J Geriatr Cardiol.2014;11 :32-8
11.Okura T. Mlyoshi K. Irita J. et al. Hyperhomocysteinemia is one of the risk factors associated with cerebrovascular stiffness in hypertensive patient, especially elderly males. Naturecom Sci Rep. 2014;4: 5663.
12.Veeranna V. Zalawadiya SK. Niraj A. Pradhan J. Ference B. Burack RC. et al. Homocysteine and reclassification of cardiovascular disease risk. J Am Coll Cardiol. 2011; 58;1025–33.
13.Blom HJ . Y Smulders Y. Overview of homocysteine and folate metabolism. With special references to cardiovascular disease and neural tube defects. J Inherit Metab Dis.2011; 34:75-81.
14.Clarke R. Halsey J. lewington S. et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality. Arch Intern Med. 2010; 170(18).
15.Chysant SG. Chysant GS. The current status of homocysteine as a risk factor for cardiovascular disease: a mini review. Expert Rev Cardiovasc Ther.2018; 16(80):559-565.
16.Martí-Carvajal AJ. Sola I. Lathyris D. Dayer M. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2017; Aug 17; 8:CD006612.
17.Djuric D. Jakovljevic V. Zivkovic V. Srejovic Homocysteine and homocysteine-related compounds: an overview of the roles in the pathology of the cardiovascular and nervous systems. Can J Physiol Pharmacol. 2018 ;96(10):991-1003.
|
|
| Add your comments about this article |
|
|
|
